title: Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis.
abstract: Growing evidence suggests that moderately elevated levels of homocysteine are associated not only with arterial thrombosis and atherosclerosis but also with venous thrombosis as well. We have reviewed recent studies that indicate that homocysteine inhibits several different anticoagulant mechanisms that are mediated by the vascular endothelium. The protein C enzyme system appears to be one of the most important anticoagulant pathways in the blood. Homocysteine inhibits the expression and activity of endothelial cell surface thrombomodulin, the thrombin cofactor responsible for protein C activation. Homocysteine inhibits the antithrombin III binding activity of endothelial heparan sulfate proteoglycan, thereby suppressing the anticoagulant effect of antithrombin III. Homocysteine also inhibits the ecto-ADPase activity of human umbilical vein endothelial cells (HUVECS). Because ADP is a potent platelet aggregatory agent, this action of homocysteine is prothrombotic. Homocysteine also interferes with the fibrinolytic properties of the endothelial surface because it inhibits the binding of tissue plasminogen activator. Homocysteine stimulates HUVEC tissue factor activity. We have found that lipoprotein(a) [Lp(a)] also stimulates HUVEC tissue factor activity. The combination of Lp(a) plus homocysteine induced more tissue factor activity than either agent alone. These disruptions in several different vessel wall-related anticoagulant functions provide plausable mechanisms for the occurrence of thrombosis in hyperhomocysteinemia.
authors.affiliation: Division of Hematology, Department of Medicine, The Mount Sinai School of Medicine, New York, NY 10029, USA.
authors.forename: P C
authors.initials: PC
authors.lastname: Harpel
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.forename: W
authors.initials: W
authors.lastname: Borth
mesh_terms: D000818:Animals; D001081:Apyrase / Q000037:antagonists & inhibitors; D004730:Endothelium, Vascular / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects*; D006497:Heparan Sulfate / Q000037:antagonists & inhibitors; D006710:Homocysteine / Q000633:toxicity*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D011486:Protein C / Q000037:antagonists & inhibitors; D013925:Thromboplastin / Q000502:physiology; D013927:Thrombosis / Q000209:etiology*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
chemical_list: D001081:Apyrase; D006497:Heparan Sulfate; D006710:Homocysteine; D011486:Protein C; D013925:Thromboplastin; D010959:Tissue Plasminogen Activator